Advertisement

Health Service Studies in the Terminally ILL Cancer Patient

  • Thomas J. Smith
Part of the Cancer Treatment and Research book series (CTAR, volume 97)

Abstract

There is a crisis in both health care spending and health care quality in the United States, regardless of our ability to ignore it. Even with projections of a budget surplus by the year 2003, the plan is still to cut Medicare by $115 billion over the next five years. Cancer care costs have risen from $35 billion in 1990 to $40 billion in 1994 to one projection of $50 billion by 1996. [1][3] Of the $191 billion spent on Medicare patients in 1996, $34 billion was spent on cancer fee for service care (Personal communication, R. Lee, Accountable Oncology Associates, 1997). Nearly one third of all Medicare spending is on patients in their last year of life; although this may be medically appropriate care, those dollars cannot be spent on preventive services or chronic disease conditions for the same population.[4][6]

Keywords

Clin Oncol Supportive Care Advance Directive Conventional Care Hospice Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brown ML: The national economic burden of cancer. JNCI 1990; 82:1811–1814.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown ML, Hodgson TA, Rice DP: Economic impact of cancer in the U.S. in Schottenfeld D, Fraumeni J (eds): Cancer, Epidemiology, and Prevention. Oxford University Press; 1996Google Scholar
  3. 3.
    Rundle RL: Salick Pioneers Selling Cancer Care to HMOs. The Wall Street Journal 1996; Monday, August 12:B1–B2.Google Scholar
  4. 4.
    Lubitz JD, Riley GF: Trends in Medicare payments in the last year of life. N Engl J Med 1993; 328:1092–1096.PubMedCrossRefGoogle Scholar
  5. 5.
    ubitz J, Beebe J, Baker C: Longevity and Medicare expenditures. N Engl J Med 1995; 332:999–1003.CrossRefGoogle Scholar
  6. 6.
    Welch HG, Wennberg DE, Welch WP: The use of Medicare home health care services. N Engl J Med 1996; 335:324–329.PubMedCrossRefGoogle Scholar
  7. 7.
    A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591–1598.Google Scholar
  8. 8.
    Cleeland CS, Gonin R, Hatfield AK, et al: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592–596.PubMedCrossRefGoogle Scholar
  9. 9.
    Farrow DC, Hunt WC, Samet JM: Geographic variation in the treatment of localized breast cancer. N Engl J Med 1992; 326:1097–1101.PubMedCrossRefGoogle Scholar
  10. 10.
    Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS: Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992; 326:1102–1107.PubMedCrossRefGoogle Scholar
  11. 11.
    Hillner BE, Penberthy L, Desch CE, McDonald K, Smith TJ, Retchin SR: Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treatment 1996; 40:75–86.CrossRefGoogle Scholar
  12. 12.
    Hillner BE, MacDonald MK, Penberthy L, et al: Measuring Standards of Care for Early Breast Cancer in an Insured Population. J Clin Oncol 1997; 15:1401–1408.PubMedGoogle Scholar
  13. 13.
    Smith TJ, Penberthy L, Desch CE, et al: Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13:235–252.PubMedCrossRefGoogle Scholar
  14. 14.
    Desch CE, Penberthy L, Newschaffer C, et al: Factors that Determine the Treatment of Local and Regional Prostate Cancer. Med Care 1996; 34:152–162.PubMedCrossRefGoogle Scholar
  15. 15.
    Hand R, Sener S, Imperato J, Chmiel JS, Sylvester J, Fremgen A: Hospital variables associated with quality of care for breast cancer patients. JAMA 1991; 266:3429–3432.PubMedCrossRefGoogle Scholar
  16. 16.
    Ayanian JZ, Kohler BA, Abe T, Epstein AM: The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993; 329:326–331.PubMedCrossRefGoogle Scholar
  17. 17.
    Levinsky NG: The purpose of advance medical planning-autonomy for patients or limitation of care? N Engl J Med 1996; 335:741–743.PubMedCrossRefGoogle Scholar
  18. 18.
    Callahan D: Controlling the costs of health care for the elderly-fair means and foul. N Engl J Med 1996; 335:744–746.PubMedCrossRefGoogle Scholar
  19. 19.
    Covinsky KE, Landefeld CS, Teno J, et al: Is economic hardship on the families of the seriously ill associated with patient and surrogate care preferences? SUPPORT Investigators. Arch Intern Med 1996; 156:1737–1741.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith TJ, Desch CE, Hillner BE: Ways to reduce the cost of oncology care without compromising the quality. Cancer Invest 1994; 12:257–265.PubMedGoogle Scholar
  21. 21.
    American Society of Clinical Oncology Outcomes Working Group (core members). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1995; 14:671–679.Google Scholar
  22. 22.
    Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300:1458–1460.PubMedGoogle Scholar
  23. 23.
    Davies E, Clarke C, Hopkins A: Malignant cerebral glioma-I: Survival, disability, and morbidity after radiotherapy. BMJ 1996; 313:1507–1512.PubMedGoogle Scholar
  24. 24.
    Davies E, Clarke C, Hopkins A: Malignant cerebral glioma-II: Perspectives of patients and relatives on the value of radiotherapy. BMJ 1996; 313:1512–1516.PubMedGoogle Scholar
  25. 25.
    Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992; 146:473–481.Google Scholar
  26. 26.
    Smith TJ: Which hat do I wear? JAMA 1993;270:1657–1659.PubMedCrossRefGoogle Scholar
  27. 27.
    Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. JNCI 1993; 85:1460–1474.PubMedCrossRefGoogle Scholar
  28. 28.
    Blair SN, Kohl HW, III., Barlow CE, Paffenbarger RS, Jr., Gibbons LW, Macera CA: Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995; 273:1093–1098.PubMedCrossRefGoogle Scholar
  29. 29.
    ouquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342:19–21.CrossRefGoogle Scholar
  30. 30.
    Adelstein DJ: Palliative chemotherapy for non-small cell lung cancer. Semin Oncol 1995;22:35–39.PubMedGoogle Scholar
  31. 31.
    American Society of Clinical Oncology: Clinical Practice Guidelines for the Treatment of Unresectable Non-Small-Cell Lung Cancer. J Clin Oncol 1997; 15:2996–3018.Google Scholar
  32. 32.
    Evans WK, Newman T, Graham I, et al: Lung Cancer Practice Guidelines: Lessons Learned and Issues Addressed by the Ontario Lung Cancer Disease Site Group. J Clin Oncol 1997; 15:3049–3059.PubMedGoogle Scholar
  33. 33.
    Jaakimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8:1301–1309.Google Scholar
  34. 34.
    Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360–367.PubMedGoogle Scholar
  35. 35.
    Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T: An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995; 13:2166–2173.PubMedGoogle Scholar
  36. 36.
    Evans WK, Will BP, Berthelot JM, Earle CC: Cost of Combined Modality Interventions for Stafe III Non-Small-Cell Lung Cancer. J Clin Oncol 1997; 15:3038–3048.PubMedGoogle Scholar
  37. 37.
    Evans WK, Will BP: The cost of managing lung cancer in Canada. Oncology Hunting 1995; 9:147–153.Google Scholar
  38. 38.
    Evans WK, Will BP, Berthelot JM, Wolfson MC: The economics of lung cancer management in Canada. Lung Cancer 1996; 14:13–17.CrossRefGoogle Scholar
  39. 39.
    Goodwin PJ, Feld R, Evans WK, Pater J: Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988; 6:1537–1547.PubMedGoogle Scholar
  40. 40.
    Glimelius B, Hoffman K, Graf W, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6:267–274.PubMedGoogle Scholar
  41. 41.
    Tannock IF, Osoba D, Stockier MR, et al: Chemotherapy With Mitoxantrone Plus Prednisone or Prednisone Alone for Symptomatic Hormone-Resistant Prostate Cancer: A Canadian Randomized Trial With Palliative End Points. J Clin Oncol 1996; 14:1756–1764.PubMedGoogle Scholar
  42. 42.
    Bloomfield DJ, Krahn MD, Tannock IF, Smith TJ: Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer (HRPC) based on a Canadian randomized trial (RCT) with palliative endpoints. Proc Am Soc Clin Oncol 1997; 17Google Scholar
  43. 43.
    Richards MA, Braysher S, Gregory WM, Rubens RD: Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67:856–860.PubMedGoogle Scholar
  44. 44.
    Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision-analysis while awaiting clinical trial results. JAMA 1992; 267:2055–2061.PubMedCrossRefGoogle Scholar
  45. 45.
    Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483–2489.PubMedGoogle Scholar
  46. 46.
    46. Welch HG, Larson EB: Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321:807–812.PubMedCrossRefGoogle Scholar
  47. 47.
    Eddy DM: What care is ‘essential’? What services are ‘basic’? JAMA 1991; 265:782,786-788.PubMedCrossRefGoogle Scholar
  48. 48.
    Kukull WA, Koepsell TD, Conrad DA, Immanuel V, Prodzkinski J, Franz C: Rapid estimation of hospitalization charges from a brief medical record review. Evaluation of a multivariate prediction model. Medical Care 1986; 24:961–966.PubMedCrossRefGoogle Scholar
  49. 49.
    Smith TJ, Hillner BE: Clinical practice guidelines...groan. Clin One Alert 1993; June: 46–48.Google Scholar
  50. 50.
    Ferris FD, Wodinsky HB, Kerr IG, Sone M, Hume S, Coons C: A cost-minimization study of cancer patients requiring a narcotic infusion in hospital and at home. J Clin Epidemiol 1991; 44:313–327.PubMedCrossRefGoogle Scholar
  51. 51.
    Wodinsky HB, DeAngelis C, Rusthoven JJ, et al: Re-evaluating the cost of outpatient cancer chemotherapy. Can Med Assoc J 1987; 137:903–906.Google Scholar
  52. 52.
    Lowenthal RM, Piaszczyk A, Arthur GE, O’Malley S: Home chemotherapy for cancer patients: Cost analysis and safety. Med J Aust 1996; 165:184–187.PubMedGoogle Scholar
  53. 53.
    Harris NJ, Dunmore R, Tscheu MJ: The Medicare hospice benefit: fiscal implications for hospice program management. Cancer Management 1996; May/June: 6–11.Google Scholar
  54. 54.
    Smith TJ: End of Life Care: Preserving Quality and Quantity of Life in Managed Care. ASCO EducBook 1997; 33rd Annual Meeting: 303–307.Google Scholar
  55. 55.
    Addington-Hall JM, MacDonald LD, Anderson HR, et al: Randomized controlled trial of effects of coordinating care for terminally ill cancer patients. BMJ 1992; 305:1317–1322.PubMedCrossRefGoogle Scholar
  56. 56.
    Raftery JP, Addington-Hall JM, MacDonald LD, et al: A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med 1996; 10:151–161.PubMedGoogle Scholar
  57. 57.
    Meier DE, Morrison RS, Cassel CK: Improving Palliative Care. Ann Intern Med 1997; 127:225–230.PubMedGoogle Scholar
  58. 58.
    McWhinney IR, Bass MJ, Orr V: Factors associated with location of death (home or hospital) or patients referred to a palliative care team. Can Med Assoc J 1995; 152:361–370.Google Scholar
  59. 59.
    Grant M, Ferrell BR, Rivera LM, Lee J: Unscheduled Readmissions for Uncontrolled Symptoms. Nursing Clinics of North America 1995; 30:673–682.PubMedGoogle Scholar
  60. 60.
    Smith TJ, Bodurtha JN: Ethical Considerations in Oncology: Balancing the Interests of Patients, Oncologists, and Society. J Clin Oncol 1995; 13:2464–2470.PubMedGoogle Scholar
  61. 61.
    Katterhagen G: Physician compliance with outcome-based guidelines and clinical pathways in oncology. Oncology 1996; November: 113–121.Google Scholar
  62. 62.
    Smith TJ: Reducing the cost of supportive care, Part I: Antibiotics for febrile neutropenia. Clin One Alert 1996; 11:46–47.Google Scholar
  63. 63.
    Smith TJ: Reducing the cost of supportive care II: Anti-emetics. Clin One Alert 1996; 11:62–64.Google Scholar
  64. 64.
    Emanuel EJ: Cost savings at the end of life. What do the data show? JAMA 1996; 275:1907–1914.PubMedCrossRefGoogle Scholar
  65. 65.
    Emanuel EJ, Emanuel LL: The economics of dying. The illusion of cost savings at the end of life. N Engl J Med 1994; 330:540–544.PubMedCrossRefGoogle Scholar
  66. 66.
    Kane RL, Berstein L, Whales J, Leibowitz A, Kaplan S: A randomized control trial of hospice care. Lancet 1984; 1:890–894.PubMedCrossRefGoogle Scholar
  67. 67.
    National Hospice Organization: An analysis of the cost savings of the medicare hospice benefit, Miami, FL, Lewin-VHI Inc; 1997Google Scholar
  68. 68.
    Kidder D: The effects of hospice coverage on Medicare expenditures. Health Serv Res 1992; 27:195–217.PubMedGoogle Scholar
  69. 69.
    Aiken LH: Evaluation and research and public policy: lessons learned from the National Hospice study. J Chronic Dis 1986; 39:1–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Brooks CH, Smyth-Staruch K: Hospice home care cost savings to third party insurers. Med Care 1984; 22:691–703.PubMedCrossRefGoogle Scholar
  71. 71.
    Stommel M, Given CW, Given BA: The cost of cancer home care to families. Cancer 1993; 71:1867–1874.PubMedCrossRefGoogle Scholar
  72. 72.
    Given BA, Given CW, Stommel M: Family and out-of-pocket costs for women with breast cancer. Cancer Pract 1994; 2:187–193.PubMedGoogle Scholar
  73. 73.
    Emanuel EJ, Emanuel LL: The Economics of Dying: The Illusion of Cost Savings at the End of Life. N Engl J Med 1994; 330:540–544.PubMedCrossRefGoogle Scholar
  74. 74.
    Teno J, Lynn J, Connors AF, Jr., et al: The illusion of end-of-life resource savings with advance directives. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 1997; 45:513–518.PubMedGoogle Scholar
  75. 75.
    Ravdin PM, Clark GM, Hilsenbeck SG, et al. A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treatment 1992; 21:47–53.CrossRefGoogle Scholar
  76. 76.
    Finkler SA: The distinction between cost and charges. Ann Intern Med 1982; 96:102–109.PubMedGoogle Scholar
  77. 77.
    Maksoud A, Jahnigen DW, Skibinski CI: Do not resuscitate orders and the cost of death. Arch Intern Med 1993; 153:1249–1253.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Thomas J. Smith
    • 1
  1. 1.Massey Cancer CenterVirginia-Commonwealth University-Medical College of VirginiaRichmond

Personalised recommendations